1. Home
  2. RVSB vs CGTX Comparison

RVSB vs CGTX Comparison

Compare RVSB & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Riverview Bancorp Inc

RVSB

Riverview Bancorp Inc

HOLD

Current Price

$5.45

Market Cap

117.2M

Sector

Finance

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.16

Market Cap

110.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVSB
CGTX
Founded
1923
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
117.2M
110.8M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
RVSB
CGTX
Price
$5.45
$1.16
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$7.00
$3.33
AVG Volume (30 Days)
30.8K
1.0M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
1.55%
N/A
EPS Growth
N/A
62.79
EPS
0.18
N/A
Revenue
N/A
N/A
Revenue This Year
$53.63
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$30.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.74
$0.22
52 Week High
$6.31
$3.83

Technical Indicators

Market Signals
Indicator
RVSB
CGTX
Relative Strength Index (RSI) 53.06 50.31
Support Level $4.90 $1.01
Resistance Level $5.57 $1.19
Average True Range (ATR) 0.19 0.10
MACD 0.01 -0.01
Stochastic Oscillator 73.17 13.04

Price Performance

Historical Comparison
RVSB
CGTX

About RVSB Riverview Bancorp Inc

Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: